Karen Pignet to Receive the 2027 Catalyst Award

WORLDSymposium is delighted to announce Karen Pignet, as the recipient of the 4th Annual Catalyst Award to be presented at WORLDSymposium 2027.
Karen is a biotech entrepreneur dedicated to advancing gene therapies for rare diseases. Following her daughter’s diagnosis with Sanfilippo syndrome, she founded Lysogene, turning a deeply personal challenge into a mission to develop a treatment for children affected by this devastating condition. After leading an investigational gene therapy for Sanfilippo syndrome type A into an international Phase III clinical trial, she founded Blue Daisy, a nonprofit organization that took over the program to bring the trial to completion. Her journey reflects a mother’s determination and an entrepreneur’s ability to mobilize people and resources to catalyze progress for patients and their families.
Karen is currently Chair and Founder of BlueDaisy. She was previously CEO of Genespire, where she led the clinical development of GENE202, a lentiviral gene therapy for methylmalonic acidemia (MMA).
She also is the Founder & Former CEO of Lysogene, which she founded In 2009, after her daughter was diagnosed with Sanfilippo syndrome. She pioneered AAV gene therapy for Sanfilippo type A, taking it into Phase 3 clinical trials and listing the company on Euronext. Lysogene was awarded the EURORDIS Company Award for Innovation under her leadership, and recognized the company for its pioneering gene therapy and its promising advances towards delivering novel treatments in neuro degenerative and neuro developmental disease areas with high unmet medical needs. The Award also celebrated the remarkable personal journey of Karen Pignet-Aiach, the company founder, as a mother, patient advocate and entrepreneur determined to change the landscape for severe rare diseases affecting children’s central nervous systems
She is a founding executive member of the International Rare Diseases Research Consortium (IRDiRC) and previously served on the Paediatric Committee at the European Medicines Agency (EMA). She was named the recipient of the 2027 WORLDSymposium Catalyst Award for her dedication to advancing rare disease gene therapies.
Please join WORLDSymposium at the 2027 Be The Catalyst at 18:00 PST on January 31, 2027, at the Manchester Grand Hyatt San Diego in San Diego, CA, where the 2027 WORLDSymposium Catalyst Award will be presented Karen Pignet. Plan to stay for the reception to reconnect with colleagues and make new connections!
About the Catalyst Award
Merriam-Webster defines a catalyst as: “an agent that provokes or speeds significant change or action.”
- The inaugural 2023 WORLDSymposium “Be The Catalyst” encouraged all attendees to be catalysts and spark change.
- In 2024, WORLDSymposium presented the first “Catalyst” award to Zachary Thomas, who was nominated in recognition of his efforts to instigate and expedite changes to newborn screening in Alabama.
- In 2025, WORLDSymposium presented the second “Catalyst” award to Ryan Colburn, who was nominated in recognition of his efforts to instigate a shift in perspective for the prevalence of Pompe disease.
- In 2026, WORLDSymposium presented the third “Catalyst” award to Professor Michael H. Gelb, who was nominated in recognition of his development of new assays for expanded Newborn Screening with a focus on lysosomal diseases.
Sign up for meeting updates to receive a notification when the award recipients are announced.
